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Previews(Nolte et al., 2009), the findings of CD70-
CD27 signaling obtained in the mouse
system, including its effect on Th17 cell
differentiation, need to be reexamined
and validated in the human immune
system. These additional studies would
be important for completely clarifying the
specificity of the CD70-CD27 axis in regu-
lating Th17 cells and laying basis for
developing therapeutics against Th17-
related inflammatory and autoimmune
diseases. Despite those remaining issues,
the study by Coquet et al. (2013) in
this issue of Immunity provides com-
pelling in vitro and in vivo experimental
evidence to support a T-cell-intrinsic role
of CD70-CD27 interaction in inhibiting
Th17 cell differentiation and migration,
adding a new brake to prevent a train
wreck of Th17-cell-mediated immunityand possibly to secure the homeostasis
of the gut-associated immune system
(Figure 1).REFERENCES
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In this issue of Immunity, studies by Blanc et al. (2013) and Liu et al. (2013) reveal how interferon induction of
cholesterol-25-hydroxylase mediates innate immunity against multiple diverse viruses.Virus infection and immune cell activation,
respectively, induce production of type I
and type II interferons (IFNs). The IFNs
are secreted and engage receptors on
cells to induce JAK-STAT signaling
pathways that activate STAT1 and
promote interferon-stimulated gene (ISG)
expression. ISG products mediate
effector actions that restrict virus infection
and modulate the immune response.
However, IFN actions are complex
and connected to the regulation of cellular
metabolic processes whose alteration
works cooperatively or even synergisti-
cally with IFNs to control infection.
Blanc et al. recently identified the regula-
tion of sterol biosynthesis as an IFN-medi-
ated antiviral strategy (Blanc et al.,
2011). This IFN-sterol crosstalk is
mediated through cholesterol-25-hydrox-
ylase (Ch25h), an ISG product thatoxidizes cholesterol to the soluble oxy-
sterol metabolite, 25-hydroxycholesterol
(25HC) (Park and Scott, 2010). 25HC has
important effects relating to lipid biosyn-
thesis and immunity. 25HC suppresses
sterol regulatory element binding protein
(SREBP)-2, a transcription factor regu-
lating the sterol biosynthesis pathway
and lipid metabolism (Brown and Gold-
stein, 1999). Additionally, activation of
Liver X receptor (LXR) by oxysterols
including 25HC modulates cholesterol
homeostasis (Ma et al., 2008). Finally,
25HC suppresses mevalonate to block
sterol biosynthesis and the production of
the prenyl lipids, farnesyl and geranylger-
anyl (Ye et al., 2003). A notable example of
mevalonate suppression in an antiviral
response is that of hepatitis C virus,
where loss of geranylgeranylation of host
proteins leads to restriction of viral repli-cation when mevalonate is limiting (Ye
et al., 2003). Moreover, these functions
of 25HC have additional effects on regula-
tion of adaptive immunity, thus under-
scoring a pivotal role for 25HC production
in antiviral immunity (Bauman et al., 2009;
Hannedouche et al., 2011).
In this issue of Immunity, Blanc et al.
(2013) assessed the connection between
IFN-mediated antiviral immunity and oxy-
sterols. The research team quantitated
the production of all known naturally
occurring oxysterols from macrophages.
They identified 25HC as the only oxysterol
produced in response to type I or type II
interferon treatment or during murine
cytomegalovirus (MCMV) infection. The
production of 25HCwas found to be regu-
lated through IFN signaling and medi-
ated by STAT1 binding to the Ch25h
promoter. Moreover, 25HC treatment of38, January 24, 2013 ª2013 Elsevier Inc. 3
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Figure 1. Interferon Induction of Ch25h and Antiviral Actions of 25HC
Type I (left) and Type II IFN (right) binding to their cognate cell surface receptor chains induces signaling of
JAK-STAT pathway components to drive gene expression from IFN-stimulated-response-elements (ISRE)
or gamma-activating-sequence elements within the promoter of the Ch25h gene to induce Ch25h expres-
sion. Ch25h catalyzes the oxidation of cholesterol to 25-hydroxycholesterol (25HC) through 02 and
NAPDH cofactors to alter cell membrane permissiveness for fusion of enveloped viruses and also restricts
viral replication.
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Previewscells resulted in an antiviral state against
MCMV. Antiviral activity of 25HC could
occur at amounts below the threshold to
induce nonspecific cytotoxicity yet higher
than those required to block sterol
biosynthesis, suggesting that 25HC acts
as an antiviral independently of SREBP
inhibition in sterol-replete conditions.
Conversely, 25HC treatment of cells
under sterol-depleted conditions led to
enhancement of 25HC antiviral actions,
suggesting that the antiviral activity of
25HC is likely mediated through multiple
processes including SREBP regulation
under conditions of variable lipid avail-
ability. The authors speculate that these
processes could include at least two
modes of concentration-dependent
25HC antiviral function: protein-specific
effects at low 25HC concentrations and
nonspecific effects on the cell membrane
at higher 25HC concentrations. 25HC-
specific antiviral actions appear to be
independent of 25HC-activation of LXR,
as LXR activation alone is insufficient to
induce an antiviral state. Also, incubation
of 25HC-treated cells with prenyl lipids
only partially rescued MCMV infectivity.
Thus, 25HC suppression of the isoprenoid
synthetic pathway of mevalonate activity
may contribute to the antiviral role of
25HC but does not act in and of itself to
block MCMV infection.
Blanc et al. (2013) also tested the ability
of 25HC to inhibit infection by a range of4 Immunity 38, January 24, 2013 ª2013 Elsevviruses. They found that influenza A virus,
herpes simplex virus-1 (HSV-1), varicella
zoster virus and murine gamma herpes
virus-68 (MHV-68) but not adenoviruses
were inhibited by 25HC, with inhibitory
concentrations dependent on the partic-
ular combination of virus and host cell.
25HC was found to have no detectable
effect on MCMV entry into the host cell
but rather mediated inhibition of viral
DNA replication. This activity is at least
partially in contrast to 25HC effects on
HSV-1, where 25HC treatment of cells
results in inhibition of viral entry. In
conclusion, the authors define 25HC as
an antiviral factor produced in response
to IFN-induced Ch25h expression and
mediating multifactorial antiviral actions.
Another study by Liu et al. (2013) inde-
pendently defined the antiviral properties
of 25HC after identifying Ch25h as an
ISG expressed within bone-marrow
derived murine macrophages treated
with Type I or II IFN. The authors conduct-
ed an unbiased ISG overexpression
antiviral screening assay of vesicular
stomatitis virus (VSV) infection that re-
vealed Ch25h as a potential antiviral
mediator. It was then found that RNAi
depletion or genetic targeting of Ch25h
led to increased susceptibility to VSV
infection in macrophage and B cell
cultures, hence the authors concluded
that Ch25h imparts an antiviral ISG
response. Moreover, Ch25h overexpres-ier Inc.sion was found to inhibit VSV through
production of a soluble factor exclusive
of IFNs and whose activity is also inde-
pendent of IFNAR and STAT1. Thus,
Ch25h likely oxidizes cholesterol to
produce 25HC, which then creates an
antiviral state within responding cells.
The 25HC antiviral response was found
to occur independently of LXR activation,
SREBP regulation, mevalonate activity,
and nonspecific cytotoxicity. Liu et al.
(2013) also demonstrated that Ch25h
induced broad-spectrum antiviral actions
to suppress infection by VSV, HIV, HSV-1,
MHV68, Ebola virus, Nipah virus, Russian
Spring-Summer encephalitis virus, and
Rift Valley fever virus (which notably are
all enveloped viruses), but not adenovirus
(a nonenveloped virus). Assessment of
the antiviral mechanism revealed that
VSV and HIV are blocked by 25HC at the
level of viral entry, specifically by inhibition
of virus-cell membrane fusion. 25HC did
not directly affect viral infectivity, but
rather reduced the permissiveness of the
host cell membrane for viral fusion. More-
over, Ch25h-deficient mice were found to
be more susceptible to MHV68 infection
in vivo, and 25HC treatment in a mouse
HIV in vivo infection model resulted in
decreased HIV loads and a reversal of
virus-mediated T cell depletion. The
authors conclude from this study that
Ch25h is an ISG that mediates the pro-
duction of the antiviral oxysterol 25HC,
which inhibits cell fusion of enveloped
viruses.
These studies differ in their conclusions
as to the mechanism by which 25HC
inhibits viral infection. Whereas Blanc
et al. (2013) determined that viral entry of
MCMV was unaffected by 25HC, Liu
et al. (2013) showed that VSV and HIV
were specifically inhibited at the level of
entry through restriction of virus-cell
membrane fusion. To explain this, the
viruses tested by each group were not
among those examined in detail across
the viral life cycle, and different viruses
likely have varying susceptibilities to
25HC regulation. The authors of both
papers agree that the pleiotropic effects
of 25HC have the potential to target viral
infection atmultiple levels throughmultiple
mechanisms, depending on the virus-host
context and the relevant nutrient host cell
metabolic conditions (Figure 1).
The antiviral activity of 25HC against
a number of viruses highlights this
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Previewsoxysterol as a potential target for antiviral
therapy. This idea is particularly intriguing
as 25HC administration restored immune
cell numbers in an HIV infection model.
Additionally, the inhibitory effect of statins
against viruses such as HCV (Ye et al.,
2003) demonstrates that modulation of
sterol and isoprenoid biosynthesis path-
ways stands as a potential mechanism
for antiviral therapy using existing thera-
peutic drugs.
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Inflammatory cytokines shape CD8+ T cell responses. In this issue of Immunity, Richer et al. (2013) and
Raue et al. (2013) demonstrate that inflammatory cytokines dynamically fine-tune antigen sensitivity of
CD8+ T cells to potently detect and better eliminate infected cells.Productive CD8+ T cell responses are crit-
ical to immune defense against invading
pathogens. In order to activate and tune
CD8+ T cell responses, cognate triggering
of the T cell receptor (TCR) and concur-
rent ligation of CD28 is not sufficient, an
additional third signal in the form of
inflammatory cytokines is required for
the differentiation of fully functional
effector CD8+ T cells (Curtsinger and
Mescher, 2010). Naive CD8+ T cells exit
the thymus with the potential to differen-
tiate into a spectrum of effector popula-
tions possessing unique capacities for
survival, proliferation, cytokine expres-
sion, cytotoxicity, and memory formation.
It is well appreciated that these defining
characteristics of the T cell response are
heavily influenced by local cytokines at
the time of priming. Currently, there is
great interest in understanding how
distinct inflammatory cytokines direct
and tune CD8+ T cell responses and thedynamic impact they have throughout
the course of infection.
It has been previously recognized that
as an infection progresses, pathogen-
specific CD8+ T cells exhibit enhanced
sensitivity to antigen (Slifka and Whitton,
2001). Considering that T cells do not
mutate their T cell receptor, how the
enhanced sensitivity is achieved has re-
mained unclear. In this issue of Immunity,
Richer et al. (2013) and Raue et al. (2013)
address this question. Richer et al. (2013)
demonstrate the important role the
inflammatory milieu plays in tuning
antigen sensitivity of CD8+ T cells via the
enhancement of proximal TCR signal
transduction. This finding suggests an
elegant mechanism by which the sensi-
tivity of local T cells is enhanced at
sites of pathogenic assault with limited
potential for systemic activation and
potential distant autoimmunity. Raue
et al. (2013) reveal the capacity of twoinflammatory cytokines, interleukin-12
(IL-12) and IL-18, to initiate an effector
program in memory CD8+ T cells in the
absence of antigen, thereby giving CD8+
T cells a head start on recurring patho-
gens and potentially accounting for
some of the rapid responsiveness to rein-
fection. Both of these articles suggest
a mechanism whereby the immune
response at the site of invasion is given
a selective advantage and provide insight
toward our understanding of how CD8+
T cell function is regulated to identify
and kill infected cells at the beginning
of infection when antigen is limited
(Figure 1).
Although the profound capacity of
inflammatory cytokines to drive prolifera-
tion and effector differentiation during
the priming of naive CD8+ T cells has
been well defined (Curtsinger and
Mescher, 2010), the impact of these cyto-
kines on fine-tuning antigen sensitivity38, January 24, 2013 ª2013 Elsevier Inc. 5
